About Seven Bridges Genomics
Seven Bridges Genomics is a company based in Cambridge (United States) founded in 2009 was acquired by Summa Equity in January 2023.. Seven Bridges Genomics has raised $113 million across 7 funding rounds from investors including HHS, European Union and First Star Ventures. The company has 112 employees as of December 31, 2022. Seven Bridges Genomics offers products and services including ARIA, GRAF, and RHEO Platform. Seven Bridges Genomics operates in a competitive market with competitors including DNAnexus, Genomics, Depixus, Ingenuity Systems and Eagle Genomics, among others.
- Headquarter Cambridge, United States
- Employees 112 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Seven Bridges Genomics Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$113 M (USD)
in 7 rounds
-
Latest Funding Round
$15 M (USD), Series C
Apr 27, 2021
-
Investors
HHS
& 4 more
-
Employee Count
112
as on Dec 31, 2022
-
Acquired by
Summa Equity
(Jan 13, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Seven Bridges Genomics
Seven Bridges Genomics offers a comprehensive portfolio of products and services, including ARIA, GRAF, and RHEO Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for secure data sharing and harmonization in research.
Tool for advancing human genome research and population studies.
Environment for pipeline development and data exploration.
Unlock access to complete
Unlock access to complete
Funding Insights of Seven Bridges Genomics
Seven Bridges Genomics has successfully raised a total of $113M across 7 strategic funding rounds. The most recent funding activity was a Series C round of $15 million completed in April 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Series C — $15.0M
-
First Round
First Round
(01 Jun 2014)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2021 | Amount | Series C - Seven Bridges Genomics | Valuation |
investors |
|
| Jun, 2018 | Amount | Series B - Seven Bridges Genomics | Valuation |
investors |
|
| Jan, 2018 | Amount | Grant - Seven Bridges Genomics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Seven Bridges Genomics
Seven Bridges Genomics has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, European Union and First Star Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments in technology startups are made by First Star Ventures.
|
Founded Year | Domain | Location | |
|
Summa Equity is focused on thematic and impact investments.
|
Founded Year | Domain | Location | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Seven Bridges Genomics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Seven Bridges Genomics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Seven Bridges Genomics Comparisons
Competitors of Seven Bridges Genomics
Seven Bridges Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as DNAnexus, Genomics, Depixus, Ingenuity Systems and Eagle Genomics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Cloud-based genome informatics and data management are provided.
|
|
| domain | founded_year | HQ Location |
Genomic risk assessment and prevention platform is provided.
|
|
| domain | founded_year | HQ Location |
Single-molecule genetic and epigenetic sequencing solutions are provided.
|
|
| domain | founded_year | HQ Location |
Genomic data is analyzed and interpreted via web-based applications.
|
|
| domain | founded_year | HQ Location |
Developer of cloud-based software solutions for genomic analysis
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Seven Bridges Genomics
Frequently Asked Questions about Seven Bridges Genomics
When was Seven Bridges Genomics founded?
Seven Bridges Genomics was founded in 2009 and raised its 1st funding round 5 years after it was founded.
Where is Seven Bridges Genomics located?
Seven Bridges Genomics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Who is the current CEO of Seven Bridges Genomics?
William A Moss is the current CEO of Seven Bridges Genomics.
Is Seven Bridges Genomics a funded company?
Seven Bridges Genomics is a funded company, having raised a total of $113M across 7 funding rounds to date.
How many employees does Seven Bridges Genomics have?
As of Dec 31, 2022, the latest employee count at Seven Bridges Genomics is 112.
What does Seven Bridges Genomics do?
Seven Bridges Genomics provides a scalable and secure cloud-platform for NGS data analysis. The platform is aimed at researchers, labs, core facilities, and pharmaceutical companies to manage large amounts of NGS data, design and run scalable analysis pipelines, and efficiently collaborate on projects. Customers of Seven Bridges include research institutions, labs, sequencing service providers, biotechnology companies, and pharmaceutical companies. The Graph Genome is a self-improving system using machine learning for representing and analyzing genomic information using graphs and can be used for variant calling and genomic analysis.
Who are the top competitors of Seven Bridges Genomics?
Seven Bridges Genomics's top competitors include DNAnexus, Eagle Genomics and Depixus.
What products or services does Seven Bridges Genomics offer?
Seven Bridges Genomics offers ARIA, GRAF, and RHEO Platform.
Who are Seven Bridges Genomics's investors?
Seven Bridges Genomics has 5 investors. Key investors include HHS, European Union, First Star Ventures, Genomics England, and Summa Equity.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.